Australia In Vitro Diagnostics (IVD) Quality Control Market (2025-2030)
The Australia In Vitro Diagnostics (IVD) Quality Control Market was valued at $12.9 Million in 2025 and projected to reach to $16.4 Million by 2030, representing a compound annual growth rate of 4.9%. Australia's IVD Quality Control Market is experiencing steady expansion as the nation's healthcare sector prioritizes diagnostic precision and regulatory compliance.
Australia In Vitro Diagnostics (IVD) Quality Control Market Trends and Insights
- Australia's healthcare sector is increasingly prioritizing diagnostic accuracy and regulatory compliance, driving demand for robust quality control solutions across clinical laboratories and diagnostic facilities.
- The market in Australia reflects the country's commitment to maintaining high standards in laboratory testing and patient safety. The growth trajectory for Australia's IVD quality control market is supported by rising laboratory automation, stringent regulatory frameworks, and the expansion of diagnostic testing capabilities across both public and private healthcare institutions.
- Australia's diagnostic laboratories are investing in advanced quality assurance systems to meet international standards and ensure reliable test results.
- Between 2025 and 2030, Australia will experience steady market expansion as healthcare providers prioritize quality control infrastructure to support precision medicine and population health initiatives..
Key Market Statistics
- CAGR (2025-2030) 4.9% CAGR
- Market Size, 2025 ~USD 12.9 Million
- Forecast, 2030 ~USD 16.4 Million
- Country Australia
Australia In Vitro Diagnostics (IVD) Quality Control Market Overview
Market Valuation :
Australia's IVD Quality Control Market is valued at USD 12.9 million in 2025, with steady growth trajectory driven by increasing laboratory automation and regulatory requirements across the country's healthcare infrastructure.
Growth Trajectory :
The market is projected to reach USD 16.4 million by 2030, representing a CAGR of 4.9%, outpacing many developed markets due to Australia's emphasis on diagnostic accuracy and compliance standards.
Regulatory Compliance Focus :
Australian clinical laboratories are increasingly adopting stringent quality control measures to meet NATA accreditation standards and TGA regulations, creating sustained demand for advanced QC solutions.
Healthcare Sector Modernization :
Australia's healthcare system is investing in diagnostic infrastructure modernization, with pathology networks and private laboratories expanding their quality control capabilities to ensure patient safety and test accuracy.
Australia In Vitro Diagnostics (IVD) Quality Control Market Dynamics
- Clinical laboratories across major cities including Sydney, Melbourne, and Brisbane are increasingly investing in automated quality control systems to meet NATA accreditation requirements and TGA standards.
- The market benefits from Australia's aging population, rising chronic disease prevalence, and government initiatives supporting diagnostic infrastructure development. Looking ahead to 2030, the market will be shaped by technological advancements in laboratory automation, integration of AI-driven quality assurance systems, and growing demand from both public and private pathology providers.
- Increased focus on point-of-care testing standardization and the expansion of regional diagnostic services will further drive adoption of quality control solutions across Australia's healthcare landscape..
Related Ecosystem
In Vitro Diagnostics
- Polymerase Chain Reaction (PCR)
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Dna Microarrays
- Assay Kits
- Microarrays
- ROCHE HOLDINGS AG
- Thermo Fisher Scientific Inc.
- Danaher Corporation
- Abbott Laboratories
- Biomerieux s.a.
Medical Devices
- Polymerase Chain Reaction (PCR)
- Magnetic Resonance Imaging (MRI)
- Disposable Autoinjectors
- Pulse Oximeters
- Blood Pressure Monitors
- Medtronic plc
- Abbott Laboratories
- Stryker Corporation
- Becton, Dickinson and Company
- JOHNSON & JOHNSON
Key Takeaways
- Australia's IVD Quality Control Market is valued at USD 12.9 million in 2025 with projected growth to USD 16.4 million by 2030.
- Australia maintains a 4.9% CAGR, reflecting steady demand for diagnostic quality assurance and regulatory compliance solutions.
- Australia's healthcare system drives adoption of advanced quality control systems through stringent laboratory standards and accreditation requirements.
- Australia's market growth is supported by laboratory automation investments and expansion of diagnostic testing across public and private sectors.
In Vitro Diagnostics (IVD) Quality Control Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2025 |
| Fastest Growing Segment | MOLECULAR DIAGNOSTICS (Technology) |
| Forecast Period | 2025–2030 |
| Growth Rate | CAGR of 5.5% from 2025 to 2030 |
| Largest Segment | QUALITY CONTROL PRODUCTS (Product & Service) |
| Market Size Base Year (Billions) | ~USD 1.65 (2025) |
| Revenue Forecast (Billions) | ~USD 2.15 (2030) |
| Segments Covered | Product & Service, Type, Technology, Manufacturer Type, End User |
Australia In Vitro Diagnostics (IVD) Quality Control Market Report Segmentation
5 segment dimensions are covered across the global market.
By Product & Service
- Data Management Solutions
- Quality Assurance Services
- Quality Control Products
By Type
- Independent Controls
- Instrument-Specific Controls
- Other Controls
- Serum/Plasma-Based Controls
- Urine-Based Controls
- Whole Blood-Based Controls
By Technology
- Clinical Chemistry
- Coagulation & Hemostasis
- Hematology
- Immunoassays
- Microbiology
- Molecular Diagnostics
- Other Technologies
By Manufacturer Type
- Original Equipment Manufacturer Controls
- Third-Party Controls
By End User
- Academic & Research Institutes
- Clinical Laboratories
- Hospitals
- Other End Users
Target Audience
- IVD Manufacturers & Suppliers : Need Australia-specific market data to develop localized product strategies, understand NATA/TGA compliance requirements, and identify distribution opportunities within the country's clinical laboratory network.
- Clinical Laboratory Operators : Require market insights to benchmark quality control investments, evaluate technology solutions aligned with Australian regulatory standards, and optimize operational efficiency across pathology services.
- Healthcare Consultants & Advisors : Need detailed Australia market analysis to advise clients on diagnostic infrastructure investments, quality assurance strategies, and competitive positioning within the country's evolving healthcare landscape.
- Private Equity & Investment Firms : Seek Australia-focused market intelligence to evaluate investment opportunities in pathology networks, diagnostic service providers, and quality control technology companies operating in the region.
- Government & Policy Makers : Require market data to inform healthcare policy decisions, diagnostic infrastructure funding, laboratory accreditation standards, and quality assurance initiatives supporting Australia's healthcare system.
Key Companies in the Australia In Vitro Diagnostics (IVD) Quality Control Market
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| BIOMERIEUX S.A. | France | Public Company | Clinical microbiology (VITEK, culture media, ID/AST, BACT/ALERT),Syndromic and molecular diagnostics (BIOFIRE, SPOTFIRE, ARGENE, NUCLISENS),Immunoassays and biomarkers (VIDAS, Hybiome CLIA, sepsis markers), |
| CEPHEID INC. | United States | Private Company | GeneXpert instruments and Xpert test cartridges,SmartCycler systems and assays,Collaborative and program-based solutions (e.g., TB, Ebola, USPS BDS), |
| IMMUCOR, INC. | United States | Private Company | Transfusion (serology instruments and reagents),Transplant & Molecular (HLA, HEA/HPA typing, Array Imaging System),Platelet-focused and specialty coagulation products, |
| DIASORIN | Italy | Public Company | Immunodiagnostics – Infectious and Gastrointestinal Diseases,Immunodiagnostics – Endocrinology and Metabolic Disorders,Oncology and Tumor Markers, |
| UNILABS | Switzerland | Private Company | Core laboratory testing,Medical imaging services,Pathology and centres of excellence, |
| BIO-RAD LABORATORIES, INC. | United States | Public Company | Clinical Diagnostics,Life Science Research Instruments and Reagents,Other and Services, |
| THERMO FISHER SCIENTIFIC, INC. | United States | Public Company | Life Sciences Solutions,Analytical Instruments,Specialty Diagnostics, |
| ABBOTT | United States | Public Company | Diagnostic Products (core lab, rapid, molecular, cardiometabolic, drug testing),Medical Devices (cardiovascular, diabetes care, neuromodulation),Nutritional Products (pediatric, adult, infant formula), |
| LGC LIMITED | South Korea | Public Company | Ethylene-based synthetic resins (EVA, HDPE, LDPE, LLDPE, POE, metallocene PE, UNIQABLE),Styrene-based resins (ABS, ASA, EPS, PS, SAN),Polycarbonate and polypropylene, |
| SIEMENS HEALTHINEERS AG | Germany | Public Company | Imaging,Diagnostics,Varian (Oncology), |
| QUIDELORTHO CORPORATION | United States | Public Company | Labs (clinical chemistry and immunoassay),Transfusion Medicine,Point of Care (professional and OTC), |
| DANAHER CORPORATION | United States | Public Company | Biotechnology (bioprocessing and related solutions),Life Sciences (research tools and genomic medicines),Diagnostics (clinical instruments and consumables), |
| SYSMEX CORPORATION | Japan | Public Company | Hematology analyzers and reagents (XN-Series, XN-V, ProCyte Dx),Coagulation systems and reagents,Blood gas, electrolyte, and urinalysis analyzers, |
| BIO-TECHNE CORPORATION | United States | Public Company | Protein Sciences reagents (cytokines, growth factors, antibodies, small molecules, sera, cell selection),Proteomic and protein analysis instruments and immunoassays,Diagnostics products, controls, calibrators, and assays, |
| MICROBIX BIOSYSTEMS INC. | Canada | Public Company | Antigen and test ingredient business,QAPs branded test controls and quality assessment products,DxTM viral transport medium, |
| GRIFOLS, S.A. | Spain | Public Company | Biopharma (plasma-derived medicines),Diagnostic,Bio Supplies, |
BIOMERIEUX S.A.
bioMérieux S.A. is a French public company founded in 1963 that employs 14,894 people. The company operates in the diagnostics and life sciences sector.
CEPHEID INC.
Cepheid Inc. is a private company founded in 1996 in the United States with 1,700 employees. The company specializes in molecular diagnostics and infectious disease testing.
IMMUCOR, INC.
Immucor, Inc. is a private company founded in 1982 in the United States with 1,125 employees. The company focuses on blood bank and transfusion diagnostics.
DIASORIN
DiaSorin is an Italian public company founded in 1968 with 3,242 employees. The company operates in the in vitro diagnostics sector.
UNILABS
Unilabs is a private company founded in 1987 in Switzerland with 1,897 employees. The company provides laboratory and diagnostic services.
BIO-RAD LABORATORIES, INC.
Bio-Rad Laboratories, Inc. is a public company founded in 1952 in the United States with 7,450 employees. The company develops and manufactures life science research and clinical diagnostics products.
THERMO FISHER SCIENTIFIC, INC.
Thermo Fisher Scientific, Inc. is a public company founded in 1956 in the United States with 125,000 employees. The company is a global leader in serving science with laboratory equipment, reagents, and analytical instruments.
ABBOTT
Abbott is a public company founded in 1888 in the United States with 115,000 employees. The company operates in diagnostics, medical devices, pharmaceuticals, and nutritional products.
LGC LIMITED
LGC Limited is a public company founded in 1947 in South Korea with 14,019 employees. The company provides testing, proficiency testing, and reference materials services.
SIEMENS HEALTHINEERS AG
Siemens Healthineers AG is a public company founded in 1896 in Germany with 72,369 employees. The company provides medical imaging, laboratory diagnostics, and point-of-care testing solutions.
QUIDELORTHO CORPORATION
QuidelOrtho Corporation is a public company founded in 1979 in the United States with 6,500 employees. The company develops and manufactures rapid diagnostic tests and molecular testing solutions.
DANAHER CORPORATION
Danaher Corporation is a public company founded in 1969 in the United States with 59,000 employees. The company operates across diagnostics, life sciences, and environmental and applied solutions segments.
SYSMEX CORPORATION
Sysmex Corporation is a public company founded in 1968 in Japan with 10,861 employees. The company manufactures hematology analyzers and other in vitro diagnostic systems.
BIO-TECHNE CORPORATION
Bio-Techne Corporation is a public company founded in 1976 in the United States with 3,100 employees. The company develops and manufactures life science tools and bioanalytical instruments.
MICROBIX BIOSYSTEMS INC.
Microbix Biosystems Inc. is a public company founded in 1988 in Canada with 100 employees. The company produces quality control materials and reference standards for diagnostics.
GRIFOLS, S.A.
Grifols, S.A. is a public company founded in 1909 in Spain with 25,000 employees. The company specializes in blood plasma derivatives and diagnostic products.
Reasons to Buy this Report
- Localized Market Intelligence : Gain comprehensive insights specific to Australia's IVD quality control landscape, including regulatory frameworks, NATA requirements, and TGA compliance standards that directly impact purchasing decisions.
- Competitive Positioning Strategy : Understand Australia's market dynamics, key players, and growth opportunities to develop targeted strategies for market entry or expansion within the country's clinical laboratory and pathology sectors.
- Investment Decision Support : Access detailed forecasts and market valuation data for Australia (USD 12.9M to USD 16.4M by 2030) to support capital allocation decisions and business case development for Australian healthcare ventures.
- Regulatory Compliance Roadmap : Identify Australia-specific compliance requirements and quality standards driving market demand, enabling product development and service offerings aligned with local healthcare regulations and laboratory accreditation needs.
- Growth Opportunity Identification : Discover emerging segments within Australia's diagnostic sector, including regional laboratory expansion, point-of-care testing standardization, and private pathology network growth driving quality control adoption.
Frequently asked questions
What is the current market size of IVD Quality Control in Australia?
Australia's IVD Quality Control Market is valued at USD 12.9 million in 2025 and is expected to reach USD 16.4 million by 2030.
What is the projected growth rate for Australia's IVD Quality Control Market?
Australia's IVD Quality Control Market is projected to grow at a CAGR of 4.9% from 2025 to 2030.
What factors are driving growth in Australia's IVD Quality Control Market?
Growth in Australia is driven by laboratory automation, stringent regulatory compliance requirements, expansion of diagnostic testing capabilities, and healthcare providers' commitment to diagnostic accuracy and patient safety.
Which sectors in Australia are adopting IVD Quality Control solutions?
Australia's clinical laboratories, diagnostic facilities, public healthcare institutions, and private diagnostic centers are actively adopting IVD quality control solutions to meet accreditation standards.
How does Australia's market compare to the Asia Pacific region?
Australia represents a significant segment within the Asia Pacific IVD Quality Control Market, with its 4.9% CAGR reflecting the country's mature healthcare infrastructure and emphasis on diagnostic quality standards.
RESEARCH METHODOLOGY
The study involved major activities in estimating the current market size for the global IVD quality controls market.
Exhaustive secondary research was done to collect information on the IVD quality controls market. The next step was to validate these findings, assumptions, and sizing estimates with industry experts across the value chain using primary research. Different approaches, such as top-down and bottom-up, were employed to estimate the total market size. After that, the market breakup and data triangulation procedures were used to estimate the market size of the segments and subsegments of the IVD quality controls market.
The four steps involved in estimating the market size are as follows:
Secondary Research
In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to identify and collect information for this study.
Primary Research
In the primary research process, various sources from the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources were mainly industry experts from the core and related industries and preferred suppliers, manufacturers, distributors, service providers, technology developers, researchers, and organizations related to all segments of this industry’s value chain. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information as well as assess prospects.
The following is a breakdown of the primary respondents:
Note 1: Others include sales, marketing, and product managers.
Note 2: Companies are classified into tiers based on their total revenue. Here’s the breakdown of tiers: Tier 1 = > USD 100 million, tier 2 = USD 10 million to USD 100 million, and tier 3 = < USD 10 million
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
Both the top-down and bottom-up approaches were used to estimate and validate the IVD quality controls market's total size. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size included the following:
Data Triangulation
After arriving at the overall market size by applying the process mentioned above, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Market Definition
IVD quality controls are standardized materials used to monitor, evaluate, and ensure the accuracy, reliability, and precision of diagnostic testing processes in clinical laboratories. These controls are designed to mimic patient samples and are produced from human-derived matrices such as serum, plasma, urine, or whole blood. IVD quality controls provide a benchmark for validating test system performance, detecting errors, and ensuring regulatory compliance across diverse diagnostic platforms.
Stakeholders
- Senior Management
- End Users
- Finance/Procurement Department
- R&D Department
Report Objectives
- To define, describe, segment, and forecast the global IVD quality controls market by product & service, technology, manufacturer type, end user, and region
- To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
- To analyze the micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall IVD quality controls market
- To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
- To forecast the size of the market segments with respect to five regions: North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
- To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies2
- To track and analyze company developments such as product launches & approvals, partnerships, acquisitions, agreements, and other developments
- To benchmark players within the IVD quality controls market using the Company Evaluation Matrix framework, which analyzes market players on various parameters within the broad categories of business strategy, market share, and product offerings
- To study the impact of AI/Gen AI on the market, along with the macroeconomic outlook for each region
Get the Full In Vitro Diagnostics (IVD) Quality Control Market Report
Full forecast, segment splits, and company analysis for all In Vitro Diagnostics (IVD) Quality Control Market.
- Canada In Vitro Diagnostics (IVD) Quality Control Market
- US In Vitro Diagnostics (IVD) Quality Control Market
- Germany In Vitro Diagnostics (IVD) Quality Control Market
- UK In Vitro Diagnostics (IVD) Quality Control Market
- France In Vitro Diagnostics (IVD) Quality Control Market
- Italy In Vitro Diagnostics (IVD) Quality Control Market
- Spain In Vitro Diagnostics (IVD) Quality Control Market
- Russia In Vitro Diagnostics (IVD) Quality Control Market
- China In Vitro Diagnostics (IVD) Quality Control Market
- Japan In Vitro Diagnostics (IVD) Quality Control Market
- India In Vitro Diagnostics (IVD) Quality Control Market
- South Korea In Vitro Diagnostics (IVD) Quality Control Market
- Brazil In Vitro Diagnostics (IVD) Quality Control Market
- Mexico In Vitro Diagnostics (IVD) Quality Control Market
- Saudi Arabia In Vitro Diagnostics (IVD) Quality Control Market
- UAE In Vitro Diagnostics (IVD) Quality Control Market
- Rest Of Europe In Vitro Diagnostics (IVD) Quality Control Market
- Rest Of Asia Pacific In Vitro Diagnostics (IVD) Quality Control Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report